Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 21,013-21,024 of 23,847
Other study type icon
CompletedNCT02488109

Refeeding to Optimize iNpatient Gains

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Palo Alto
Eating disordersOtherFrom 12 Years to 24 Years
Countries
United States
Sponsor
University of California, San Francisco
Condition
Eating disorders
Device study icon
CompletedNCT00822601

Repetitive Transcranial Magnetic Stimulation Efficacy on OCD (OCD)

This summary needs review. Please check the official study record and contact the research team for details.

In Paris
OCDDeviceA study involving a tool, app, wearable, test, or medical device.From 18 Years to 65 Years
Countries
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Condition
OCD
Drug study icon
CompletedNCT00277654

Risperidone Monotherapy for anxiety

This study is completed in the United States. It is testing risperidone Monotherapy for anxiety.

In Cincinnati
Bipolarity, AnxietyDrugOver 18 Years
Countries
United States
Sponsor
Lindner Center of HOPE
Condition
Bipolarity, Anxiety
Behavioral study icon
CompletedNCT03249857

Sensorimotor Compatibility Effects in Bipolarity.

This study exists to see whether the medication Sensorimotor can play a useful role in care. Researchers are trying to understand whether the medication Sensorimotor can improve attention, thinking, or day-to-day functioning.

In Saint-Etienne
BipolarityBehavioralFrom 18 Years to 55 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Condition
Bipolarity
Drug study icon
CompletedNCT00711269

SM-13496 (Lurasidone HCl) in people with Schizophrenia

This study exists to compare options and see whether the medication SM-13496 offers something meaningfully different. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

Multiple locations, including Tokyo, Etc.
SchizophreniaDrugFrom 18 Years to 74 Years
Countries
Japan, South Korea, Taiwan
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
Drug study icon
Active Not RecruitingNCT06442462

SPG302 in Adults With Schizophrenia

This study is comparing SPG302 with placebo for people with Schizophrenia. Participants receive SPG302 or placebo and complete study visits and assessments.

Multiple locations, including Garden Grove
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Australia
Sponsor
Spinogenix
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.